Personalized IV antibiotics for serious Staph aureus infections
Part of Infections clinical trials.
This Phase 2 study tests whether continuous IV antibiotics plus “drug level monitoring” (TDM) works better than the usual treatment for complicated Staph aureus infections. It may help ensure the antibiotic dose stays in an effective range while you’re being treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to give consent (or have a legal representative if needed)
- Have a complicated Staph aureus infection, such as Staph in the blood or a deep infection like bone/joint infection or a deep abscess
- Be starting or already receiving flucoxacillin (FLU) or cefazolin (CZO) through an IV within the last 24 hours
- Not be on hemodialysis, and have kidney function not extremely low (eGFR 10 or above)
- Not have MRSA (a resistant type of Staph aureus) or severe liver scarring/cirrhosis (Child B or C)
- Not be taking other investigational study drugs within the last 30 days and not be likely to stop or leave the hospital within 48 hours
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding linezolid, an antibiotic that stops bacteria from making proteins, to usual care works better for treating Staphylococcus aureus bloodstream infections. You may be eligible if you have this infection and are hospitalized.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This study tests two ways of giving the antibiotic ceftazidime/avibactam (as a continuous drip or as intermittent shots) to patients in the intensive care unit with severe infections. The goal is to see which method works better or is safer for critically ill patients.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
Hear when a new Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.